Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Are the Projected Market Size and Growth Rates for the Guillain-Barre Syndrome Market From 2025 To 2029?
In recent times, the market size for Guillain-Barre Syndrome (GBS) has seen robust growth. The market, which stands at $0.60 billion in 2024, is projected to expand to $0.64 billion in 2025, driving a compound annual growth rate (CAGR) of 5.9%. Several factors have spurred this growth in the historic period, including a burgeoning demand for GBS treatments, an uptick in viral infections, intensifying worldwide vaccination initiatives, deepening comprehension of autoimmune mechanisms, and a rising consciousness and diagnosis rate.
Strong expansion is anticipated for the Guillain-Barre syndrome market in the coming years, with projections indicating it will reach a value of $0.79 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.6%. This projected growth could be ascribed to factors such as the rising incidence of Guillain-Barre syndrome, the impacts of climate change, higher utilization of immunotherapies and medications, the escalation in diagnostic competences, and an increase in the rates of multifocal motor neuropathy. Key future trends encompass advancements in diagnostic procedures, the advent of immunoglobulin treatments, betterment of plasmapheresis techniques, the pursuit of gene therapy, an emphasis on early intervention, new prognosis biomarkers, and broader clinical investigations for innovative therapies.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21198&type=smp
Which Factors and External Forces Are Driving Demand in the Guillain-Barre Syndrome Market?
The escalation in immunological diseases is anticipated to drive the growth of the guillain-barre syndrome market. Such conditions occur when the immune system becomes too active, too passive, or misdirected, leading to disorders like autoimmune diseases, allergies, or immunodeficiencies. The increase in these diseases can be attributed to factors such as environmental changes, lifestyle shifts, improved diagnostics, and genetic factors. An autoimmune response triggered by these diseases can lead to guillain-barré syndrome, where the body’s immune system erroneously attacks the peripheral nerves causing inflammation and nerve damage. For example, in July 2024, data from the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Swiss-based government body, showed that about 39.5 million individuals globally were living with HIV at the end of 2022, with 1.3 million new infections and 630,000 AIDS-related deaths reported that year. By 2023, the number of people infected with HIV globally increased to nearly 39.9 million. Consequently, the heightened risk of immunological diseases is propelling the guillain-barre syndrome market.
Which Segments in the Guillain-Barre Syndrome Offer the Most Growth?
The guillain-barre syndrome market covered in this report is segmented –
1) By Type: Acute Inflammatory Demyelinating Polyneuropathy (AIDP), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN), Other Types
2) By Therapeutics: Intravenous Immunoglobulin (IVIG), Plasma Exchange, Other Therapeutics
3) By Route Of Administration: Parenteral, Oral
4) By End User: Hospitals, Clinics, Diagnostic Centers, Other End Users
Subsegments:
1) By Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Classical AIDP, AIDP with Autonomic Involvement
2) By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Progressive CIDP, Relapsing-Remitting CIDP, Multifocal CIDP
3) By Miller Fisher Syndrome (MFS): Classical MFS, MFS With Ataxia, MFS With Ophthalmoplegia
4) By Acute Motor Axonal Neuropathy (AMAN): Classical AMAN, AMAN with Respiratory Involvement
5) By Other Types: Acute Sensory Ganglionopathy, Variants With Cranial Nerve Involvement, Bickerstaff Brainstem Encephalitis
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21198&type=smp
What Are the Fastest-Growing Geographies in the Which Factors and External Forces Are Driving Demand in the Guillain-Barre Syndrome Market? Market?
North America was the largest region in the guillain-barre syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Cutting-Edge Market Trends Are Expected to Drive theGuillain-Barre Syndrome Market’s Growth?
Leading corporations in the Guillain-Barre syndrome market are focusing on the development of innovative drugs such as monoclonal antibodies, with the goals of improving treatment effectiveness, addressing unmet medical needs, and broadening their market footprint. Monoclonal antibodies are proteins engineered in a lab to focus on specific antigens, contributing to the moderation of immune responses and the enhancement of therapeutic outcomes. For example, the US-based biopharmaceutical firm, Annexon Inc., was granted orphan drug status by the European Medicines Agency (EMA) in October 2023 for its ANX005 drug for treating Guillain-Barre syndrome (GBS). This monoclonal antibody, which targets C1q, has shown early improvements in muscle strength and a decreased reliance on ventilation compared to IVIg, signifying a substantial progression in therapy.
View the full report here:
https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-global-market-report
What Are the Key Elements That Define the Guillain-Barre Syndrome Market?
Guillain-barre syndrome is a rare neurological disorder in which the body’s immune system mistakenly attacks the peripheral nervous system. This can lead to muscle weakness, numbness, tingling, and, in severe cases, paralysis. The exact cause is unknown, but it is triggered by infections, such as respiratory or gastrointestinal infections, and sometimes by vaccinations or surgery.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21198
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
